The risk for developing the skin condition bullous pemphigoid was higher among patients with type 2 diabetes who used dipeptidyl peptidase-4 inhibitors, compared with those who used second-generation sulfonylureas, according to a study in JAMA Dermatology. The cohort study of 1,664,880 patients with type 2 diabetes also revealed a greater association between increased risk of bullous pemphigoid and DPP-4 inhibitors, compared with sulfonylureas, among those who were white, 65 years or older and linagliptin users.
DPP-4 inhibitors raise bullous pemphigoid risk in T2D
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.